Fulcrum Therapeutics develops small molecule drugs designed to regulate gene expression for the treatment of genetically defined rare diseases. The company focuses its clinical efforts on hematology indications, including therapies intended to elevate fetal hemoglobin levels in patients with sickle cell disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -17.7 | — |
| Q2 2025 | 0 | — | -17.3 | — |
| Q3 2025 | 0 | — | -19.6 | — |
| Q4 2025 | 0 | — | -20.3 | — |
| Q1 2026 | 0 | — | -18.9 | — |
| Q2 2026 | 0 | — | -26.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hawthorn Bancshares, Inc. (HWBK), Bradbury Capital Inc. (BBCI), GSR IV Acquisition Corp. (GSRFU), trivago N.V. (TRVG), National Bankshares, Inc. (NKSH), Powerus Corporation (PUSA)